The anti-cancer device, Cytotron, developed by Bangalore-based Rajah Vijay Kumar received a “breakthrough” designation from the U.S. FDA’s Center for Devices and Radiological Health for the treatment of liver, pancreatic and breast cancers. Having this designation means that there is evidence that the drug or therapy that treats a serious condition, in this case, a device, demonstrates “substantial improvement on a clinically significant endpoint(s) over available therapies.” With it, the review and development of the treatment will be expedited so that it will be available as soon as it can be concluded that the benefits justify the risks, considering the...